uniQure enrolls first two patients in second cohort phase I/II trial of AMT-130 07:18 QURE uniQure N.V. announced that the first two patient procedures have been completed in the higher dose, second cohort of the Phase I/II clinical trial of AMT-130 for the treatment of Huntington's disease. The initiation of patient enrollment in this 16-patient cohort follows a meeting last month of the trial's independent Data Safety Monitoring Board that reviewed safety data for the fully enrolled first cohort of ten patients. The Phase I/II study is a double-blind, randomized clinical trial being conducted in the United States.
eBay volume appears to be tracking in-line, says Baird 06:45 EBAY
Evoqua Water price target raised to $38 from $34 at RBC Capital 06:36 AQUA, XYL RBC Capital
Cathie Wood's ARK Investment bought 142K shares of Blade Air Mobility on Tuesday 06:17 BLDE
Aclaris Therapeutics price target raised to $50 from $40 at H.C. Wainwright 06:13 ACRS H.C. Wainwright analyst…
ACRS-$17.75<------